Phaseline

Targets › F13A1

F13A1 (Coagulation factor XIII A chain): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Hematology; next expected readout Jun 2028.

Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. (UniProt, P00488)

Open in Phaseline: the race on F13A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Christian HaslingerFibrogammin (DRUG)
Coagulation factor XIII (FXIII) replacement
F13A1Phase 4Postpartum HemorrhageJun 2028

Conditions

Postpartum Hemorrhage (1)

Modalities

protein or peptide (1)

Companies

Christian Haslinger (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.